Grants and Contributions

Customer and Market Data Machine Learning Layer enables businesses to get highly-accurate & rich data of customers which will reduce costs of marketing and cost of manual research and data entry.

Contribute to the R&D work of specific applicable initiatives through modelling, software development, and technical writing of reports such as process documentation, certification, compliance, project proposals and patent filings.

With the recent launch of Talent Resilience Platform on October 8th, 2020, one of the Plum's core Go-To-Market strategies is focused on moving “upmarket” to target enterprise companies with 5,000 or more employees.

Plum needs to enhance its marketing capacity targeting senior HR executives at enterprise companies to increase the volume of marketing and sales generated leads in order to close the required amount of new customer deals needed to achieve FY21 revenue targets.

Conduct a full market analysis and prepare a business plan as a software vendor

Development of new data architecture and enhancement of system components to meet the needs of evolving requirements and technology.

To develop an all-electric transport refrigeration system to be used for freezer applications < -20°C.

Engage and collaborate with external (to MDI Solutions) standards expert(s) to gather the knowledge required to build/incorporate the FHIR data standard into MDI’s integration engine software, MD Link.

Assess and improve the resilience of the cloud-based infrastructure to withstand mass surges in public facing patient encounter volume by performing rigorous testing simulation scenarios until architecture failure in controlled staging deployments.

Germany BMWi ARIBIC consortium project led by KION Group (Germany) titled “Artificial Intelligence based Indoor Cartography”.

This Project proposes a modeling platform to quickly explore vaccine designs using simulation and Machine Learning algorithms. A recently developed base model describes the life-cycle of the virus and includes a general immune response. Extension of the model to study pathogen mutation and ‘viral fitness’ is currently underway. The main focus of the proposed work will be the development of a complementary mathematical model that rigorously describes the host immune system to elucidate the complex interactions between interferon signaling pathways and the adaptive immune response to SARS-CoV-2 infection. Collectively these models will be crucial to defining vaccine strategies, and will provide a qualitative and quantitative platform to test and guide vaccine development.
Since December 2020, there has been a few new strains of the coronavirus. Namely the UK (SARS-CoV-2 VOC 202012/01) and South Africa strain (501Y.V2) are among the more prevalent. The UK strain has already spread to Canada. The current vaccine was not developed with these new strains in mind. For that matter, further mutation of the virus can be anticipated. The current distributed vaccine that was approved in the interim is a mRNA based vaccine. While this vaccine completed clinical trials overseas, it was not tested in Canada and Health Canada have an interim approval due to the emergency. There are many vaccine candidates using other technologies that are currently in development in Canada and overseas such as instance Providence Therapeutics, Medicago, and VBI. This Project proposes a modeling framework that can be applied to test new candidates and compare to those that have been approved/distributed in Canada.
There are significant values in testing vaccines against new strains of the virus and optimizing current vaccine design against new strains. The Project’s mathematical model can be quickly modified to rapidly address the new challenges SARS-CoV-2 variants pose.